Citations

Clear

4207 citation(s) found for "Chen, Yu".

Multi-center evaluation of radiomics and deep learning to stratify malignancy risk of IPMNs
Bejar, Andrea Mia, Gonzalez, Maria , Hong, Ziliang , Aktas, Halil Ertugrul , Zhang, Zheyuan , Pan, Hongyi, Jozwiak, Zeynep Sue, Bol, Fergan , Zhao, Lili , Kartal, Gulbiz Dagoglu, Agarunov, Emil, Bruno, Marco J. , Huang, Chenchang, Gonda, Tamas A. , Bolan, Candice W. , Keswani, Rajesh N. , Tiwari, Pallavi , Bolan, Candice, Gonzalez, María Jaramillo, Durak, Görkem , Keleş, Elif , Pan, Hongyi , Jozwiak, Zeynep Sue, Chen, Chao , Spampinato, Concetto , Medetalibeyoğlu, Alpay , Ertürk, Şükrü Mehmet , Velichko, Yury , Xu, Ziyue , Jambawalikar, Sachin , Schoots, Ivo G. , Huang, Chenchang, Miller, Frank H. , Wallace, Michael B. , Tiwari, Pallavi , Bağcı, Ulaş

Mayo Clinic

No container title available | May 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6622868/v1 | PMID 40502758 Get It

Abstract Distinguishing high-risk intraductal papillary mucinous neoplasms (IPMNs), pancreatic cysts requiring surgery, from low-risk lesions remains a clinical challenge, often resulting in unnecessary procedures due to limited specificity of current methods. While radiomics and deep learning (DL) have been explored for pancreatic cancer, cyst-level malignancy risk stratification of IPMNs remains untapped. We conducted a multi-institutional study (seven centers, 359 T2W MRI images) to assess the feasibility of AI for predicting IPMN dysplasia grade using cyst-level image features. We developed and compared 2D and 3D radiomics-only, deep learning (DL)-only, and radiomics-DL fusion models, using expert radiologist scoring as a baseline reference. Model performance was evaluated using held-out test data. The radiomics-DL fusion model showed the highest discriminatory ability on the test set (AUC 0.692), outperforming the radiomics-only model (AUC 0.665). Expert accuracy varied widely (37.4%-66.7%). The fusion model integrating deep learning and radiomics features from routine T2W MRI (AUC: 0.692) demonstrates potential for objective, cyst-level risk stratification of IPMNs in a multi-center cohort, outperforming both radiomics-only models and expert radiologists. While performance requires improvement for standalone clinical use, this approach offers a scalable, non-invasive method to potentially improve diagnostic accuracy and reduce unnecessary surgical interventions.
DiSC: a statistical tool for fast differential expression analysis of individual-level single-cell RNA-seq data
Zhang, L. , Yang, Lu , Ren, Yingxue , Zhang, Shuwen , Guan, Weihua, Chen, Jun , Guan, Weihua , Zhang, Lujun , Chen, Jun , Zhang, Shuwen

Mayo Clinic

Bioinformatics | May 30, 2025 | Volume: 41 | Issue: 6 | Pages: No page available

10.1093/bioinformatics/btaf327 | PMID 40444783 Get It

Abstract Motivation Single-cell RNA sequencing (scRNA-seq) has become an important method for characterizing cellular heterogeneity, revealing more biological insights than the bulk RNA-seq. The surge in scRNA-seq data across multiple individuals calls for efficient and statistically powerful methods for differential expression (DE) analysis that addresses individual-level biological variability. Results We introduced DiSC, a method for conducting individual-level DE analysis by extracting multiple distributional characteristics, jointly testing their association with a variable of interest, and using a flexible permutation testing framework to control the false discovery rate (FDR). Our simulation studies demonstrated that DiSC effectively controlled the FDR across various settings and exhibited high statistical power in detecting different types of gene expression changes. Moreover, DiSC is computationally efficient and scalable to the rapidly increasing sample sizes in scRNA-seq studies. When applying DiSC to identify DE genes potentially associated with COVID-19 severity and Alzheimer’s disease across various types of peripheral blood mononuclear cells and neural cells, we found that our method was approximately 100 times faster than other state-of-the-art methods and the results were consistent and supported by existing literature. While DiSC was developed for scRNA-seq data, its robust testing framework can also be applied to other types of single-cell data. We applied DiSC to cytometry by time-of-flight data, DiSC identified significantly more DE markers than traditional methods. Availability and implementation The R software package “SingleCellStat” is freely available on CRAN (https://cran.r-project.org/web/packages/SingleCellStat/index.html) and GitHub (https://github.com/Lujun995/DiSC). The replication code for reproducing the analyses in this study is publicly accessible at https://github.com/Lujun995/DiSC_Replication_Code. The scRNA-seq expression matrix and metadata utilized in our simulations and analyses can be retrieved from https://cells.ucsc.edu/autism/rawMatrix.zip, https://cellxgene.cziscience.com/collections/1ca90a2d-2943-483d-b678-b809bf464c30, and https://covid19.cog.sanger.ac.uk/submissions/release1/haniffa21.processed.h5ad.
ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.
Schuetze, Scott M. , Chen, Alice P. , Jonczak, Emily , Tine, Brian Andrew Van, Gore, Steven , Fletcher, Jonathan A., Haddox, Candace L. , Ballman, Karla V. , Nassif, Elise F. , Burgess, Melissa , Cavalcante, Ludimila , George, Suzanne

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps11585 Get It

TPS11585 Background: Soft tissue sarcomas (STS) with genomic complexity are often aggressive but may be sensitive to further genotoxic stress. Leiomyosarcoma (LMS), a common STS, frequently harbors genomic complexity and DNA damage response (DDR) dysregulation. Preclinical data showed hyper-dependency on DNA-PK-mediated non-homologous end joining (NHEJ) DDR, and low-dose liposomal doxorubicin (LD-LPD) synergized with the DNA-PK inhibitor peposertib to inhibit tumor growth in LMS models. We hypothesize that a low, sensitizing dose of LPD enhances DNA damage and safely synergizes with peposertib in LMS and other genomically complex STS. Methods: This phase 1, open label, multicenter dose escalation and dose expansion study (NCT05711615) evaluates LD-LPD given intravenously (IV) on day 1 of 28-day cycles with peposertib given orally (PO) twice daily (BID) continuously (Table). Up to 18 patients (pts) over 18 years-old with advanced or unresectable LMS, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, and synovial sarcoma, ECOG performance status ≤2, who received ≥1 prior line of systemic therapy (including anthracycline ≤300 mg/m 2 ) are eligible for dose escalation. Dose expansion will include 12 pts with LMS. The primary objective is to determine the recommended phase 2 dose of LPD+peposertib based on the dose limiting toxicity rate. The Bayesian Optimal Interval (BOIN) design will inform dose escalation decisions. Secondary endpoints for the expansion cohort include adverse event rate, progression-free survival, and objective response rate per RECIST v1.1. Potential predictive biomarkers and changes in DDR biomarkers will be evaluated on biopsies during screening and at cycle 1 day 7. Circulating tumor DNA (ctDNA) collected at baseline (dose escalation and dose expansion), on treatment and at progression (dose expansion) will be correlated with disease activity and response. This trial activated on 8-May-2023 through the Experimental Therapeutics Clinical Trials Network (ETCTN) and is enrolling at select sites in the United States. Dose escalation is ongoing as of January 2025. Clinical trial information: NCT05711615 . Planned dose levels for dose escalation. Dose Escalation Schedule Dose Level Dose Liposomal doxorubicin Peposertib (tablet) -1 10 mg/m 2 IV 50 mg PO BID 0* 10 mg/m 2 IV 100 mg PO BID +1 10 mg/m 2 IV 150 mg PO BID +2 10 mg/m 2 IV 200 mg PO BID +3 15 mg/m 2 IV 200 mg PO BID +4 20 mg/m 2 IV 200 mg PO BID *Starting dose.
Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
Deshmukh, Sachin Kumar , Wu, Sharon , Xiu, Joanne , Yao, Song, Sudmeier, Lisa , Kaliński, Paweł , Repasky, Elizabeth A. , Leone, José Pablo , Chumsri, Saranya , Sledge, G. W., Hong, Chi‐Chen , Yao, Song , Chalasani, Pavani , Ernstoff, Marc S. , Graff, Stephanie L. , Lustberg, Maryam B. , Kalinsky, Kevin M. , Gandhi, Shipra

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 1107-1107

10.1200/jco.2025.43.16_suppl.1107 Get It

1107 Background: Chronic stress-mediated β2-adrenergic receptor (β2-AR) signaling promotes tumor growth via immunosuppression in the tumor microenvironment (TME) in preclinical models. Blockade of β2-AR has shown higher survival benefit in patients with TNBC in observational studies compared to other breast cancer (BC) subtypes. However, the molecular and immunological features associated with ADRB2 (gene for β2-AR) gene expression in TNBC are unknown, prompting this investigation. Methods: 3,038 TNBC samples were analyzed via NGS (592-gene panel, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences, Phoenix, AZ). Immune cell fractions were calculated by deconvolution of WTS: Quantiseq. TNBC ADRB2 -high(H) and ADRB2 -low(L) RNA expression were classified as above or below the 50 th percentile, respectively. Real-world overall survival (OS) was obtained from insurance claims and calculated from tissue collection to last contact using Kaplan-Meier estimates. Statistical significance was assessed using chi-square and Mann-Whitney U tests with multiple comparison adjustments (q < 0.05). Results: ADRB2 gene expression was lowest in TNBC (median (TPM: 1.6) compared to N = 453 HR-HER2+ (1.9), N = 629 HR+HER2+ (2.0) and N = 4,918 HR+HER2- (2.2) BC (all q < 0.05). African American or Black patients (N = 670) had lower expression of ADRB2 compared to European American or White (N = 1,412) TNBC patients (1.3 vs 1.7, q < 0.05). ADRB2 -H TNBC had higher mutation frequency of PIK3CA (21% vs 15.4%), CDH1 (7% vs 3.5%), NF1 (8% vs 4%), AKT1 (3.5% vs 2.1%), but lower frequency of TP53 (81.6% vs 87.5%), NOTCH1 (2.5% vs 4.5%) and NOTCH3 (4.4% vs 11.7%) compared to ADRB2 -L, all q < 0.05. ADRB2 -H had greater PD-L1 (22C3) positivity (39.1% vs 30.2%, q < 0.05), higher % of B cells (4.5 vs 3.4), M1 Mφ (3.4 vs 2.8), M2 Mφ (3.9 vs 2.2), Tregs (2.2 vs 1.3), NK cells (3.1 vs 2.6), DC (3.1 vs 2.9), CD8 + T cells (0.9 vs 0.2), all q < 0.05. ADRB2 -H TNBC had higher T-cell inflamed score (95 vs -80), IFN γ score (-0.23 vs -0.37), MAPK activation score (-0.46 vs -1.7), all q < 0.05; and higher expression of immune checkpoint genes ( CD274, PDCD1, PDCD1LG2, CTLA4, LAG3, HAVCR2, FOXP3, IDO1, TNFSF14, TIGIT, BTLA, CEACAM1, CD47, CD274 ; fold change: 1.6-3.7, all q < 0.05). ADRB2 -H tumors had higher expression of genes related to inflammatory response, IFNγ response, IL6-JAK-STAT3 signaling (normalized enrichment score (NES): 1.9 – 2.1), while ADRB2 -L had enrichment of MYC targets V1, MYC targets V2, E2F targets and G2M checkpoint (NES: 2.5 – 4.2), all FDR < 0.01. ADRB2 -H TNBC had better OS (mOS: 23.6 vs 18.6 months; HR 0.81, 95% CI 0.73-0.89, p < 0.0001) compared to ADRB2 -L. Conclusions: High ADRB2 expression in TNBC is associated with better survival and an immune enriched TME, elevated immune checkpoints and other targetable vulnerabilities. Future studies are needed to investigate ADRB2 as a potential stress biomarker and therapeutic target.
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Wudhikarn, Kitsada , Chen, Min , Baird, John H. , Gowda, Lohith , Rangarajan, Hemalatha G. , Abid, Muhammad Bilal , Kharfan‐Dabaja, Mohamed A. , Ganguly, Siddhartha , Young, Jo‐Anne H. , Sharma, Akshay , Modi, Dipenkumar , Salem, Baheyeldin , Vergidis, Paschalis , Smith, Melody , Boghdadly, Zeinab El , Dandoy, Christopher E. , Huppler, Anna R. , Chemaly, Roy F. , Hill, Joshua A. , Riches, Marcie , Herr, Megan M. , Martens, Michael J , Baird, John , Rangarajan, Hemalatha G , Abid, Muhammad Bilal , Kharfan-Dabaja, Mohamed A , Young, Jo-Anne H , Sharma, Akshay , Fatobene, Giancarlo , Jain, Tania , Modi, Dipenkumar , Grover, Natalie S , Salem, Baheyeldin , Batista, Marjorie Vieira , Vergidis, Paschalis , Yin, Dwight E , Kelkar, Amar H , Nishihori, Taiga , Holter Chakrabarty, Jennifer , Gergis, Usama , Smith, Melody , Dandoy, Christopher E , Murthy, Hemant S , Huppler, Anna R , Perales, Miguel-Angel , Chemaly, Roy F , Hill, Joshua A , Auletta, Jeffery J , Martens, Michael J. , Williams, Kirsten M. , Jain, Tania , Kanakry, Christopher G. , Grover, Natalie S. , Beitinjaneh, Amer , Nishihori, Taiga , Holter‐Chakrabarty, Jennifer , Murthy, Hemant S. , Perales, Miguel‐Angel , Auletta, Jeffery J.

Mayo Clinic

Blood Advances | May 28, 2025 | Volume: 9 | Issue: 21 | Pages: 5460-5472

10.1182/bloodadvances.2025016141 | PMID 40435511 Get It

Abstract Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 patients with R/R LBCL receiving commercial CD19 CAR T-cell therapy (n = 2804 axicabtagene ciloleucel [axi-cel], n = 546 tisagenlecleucel) from December 2017 to June 2022. Infection developed in 834 patients (24.9%) within 100 days after infusion, resulting in an infection density of 0.43 per 100 patient days and a 100-day cumulative incidence of 22%. Bacterial, viral, and fungal infections were recorded in 527 (15.7%), 374 (11.2%), and 108 patients (3.2%), respectively, with corresponding infection densities of 0.23, 0.15, and 0.04 per 100 patient days. After a 24-month median follow-up, 1482 patients (44%) had died, with infection as the primary cause in 173 cases (12%). The 100-day infection-related mortality (IRM) was 1.6% (95% confidence interval, 1.2-2.0). Patients with a Karnofsky performance score of ≤80, infection history before CAR T-cell therapy, axi-cel therapy, severe cytokine release syndrome (grade ≥3), and severe immune effector cell–associated neurotoxicity syndrome (grade ≥3) had increased infection risk. Infections within 100 days were an independent risk factor for inferior overall survival beyond day 100 after CD19 CAR T-cell therapy. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell therapy. Furthermore, results identify patients at a heightened risk of infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy.
Reviews of "Transient JAK/STAT Inhibition by Ruxolitinib Modulates Malaria-specific CD4+ T Cell Responses and Enhances Recall Immunity in Volunteers Experimentally Infected with Plasmodium Falciparum"
Chen, Qijun , Silva, Henrique Borges da , Forconi, Catherine Suzanne

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.0849bb70 Get It

Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
Chien, Jo, Norwood, Peter, Wei, Mei , Chen, Nan , Borowsky, Alexander D. , Melisko, Michelle , Mukhtar, Rita A. , Giridhar, Karthik V. , Goetz, Matthew P. , Vaklavas, Christos , Elias, Anthony , Rugo, Hope S. , Swigart, Lamorna Brown , Shatsky, Rebecca , Huppert, Laura Ann , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 604-604

10.1200/jco.2025.43.16_suppl.604 Get It

604 Background: The addition of OFS to standard endocrine therapy (ET) improves iDFS for preM women with early-stage hormone receptor positive (HR+) breast cancer (BC). Incomplete OFS occurs in a subset of women, the long-term clinical significance of which is unclear. This study evaluates local sE2 levels in preM women receiving OFS with an oral SERD in the neoadjuvant (NA) setting. Methods: The EOP is a I-SPY2 sub-study investigating NA endocrine-based strategies in pts with HR+ HER2- Stage 2/3 BC predicted to have lower benefit from chemotherapy. Pts were randomized to oral amcenestrant 200 mg/d, alone or in combination with either letrozole 2.5 mg/d or abemaciclib 150 mg bid. Additional pts were randomized to a standard of care (SOC) arm consisting of an aromatase inhibitor. All PreM pts received OFS with monthly GnRHa up to 2 wks prior to C1D1 of study therapy. Pts were treated for 6 months prior to surgery. sE2 levels were collected locally prior to each GnRHa injection. Tumor Ki67 was assessed at 3 weeks and surgery, and associated with sE2 level. Statistical significance was determined using a two-sided Student’s t-test and a significance level 0.05. Results: Between 5/2021-8/2022, 74 pts were enrolled to an amcenestrant containing arm, 40 of whom were preM. 38/40 pts had at least one local sE2 level measured in follow up. Of these 38 pts (median age 45 years), 37 suppressed sE2 into the postmenopausal (postM) range at one or more follow-up timepoints. Of the 37 pts that completely suppressed into the postM range, 6 pts had sE2 levels rebound into the preM range (mean 319 pg/mL, range 20-848 pg/mL) with peak sE2 levels occurring at a median of 12 weeks from C1D1. One pt never suppressed to the postM range (peak sE2 1227 pg/mL) and was found to have an ovarian cyst after 3 months on amcenestrant, requiring surgery. One additional pt had multiple ovarian cysts (sE2 84 pg/mL). Median age of the 7 pts who had sE2 rebound was 43 years. There was no significant difference in Ki67 at 3 weeks and surgery between pts whose sE2 levels remained suppressed (median Ki67 2.0%) compared to those whose estradiol rebounded into the preM range or never suppressed (median Ki67 1.5%). In the 5 pts whose sE2 rebounded to > 200 pg/mL, all pts had tumor Ki67 < 10% at 3 weeks and surgery. Between 12/2022 and 8/2023, 20 pts were enrolled to AI +/- OFS and 11 pts were preM. Of the 11 preM pts, all pts suppressed sE2 to the postM range. No SOC patients had sE2 levels rebound into the preM range. Conclusions: In this study of neoadjuvant oral SERD with monthly OFS, 7/38 (18.4%) preM pts had sE2 levels remain or rebound into the preM range. sE2 levels did not appear to impact Ki67 suppression on NA ET. Work up for ovarian cysts should be considered in pts with symptoms, or significantly elevated or persistent sE2 levels. Clinical trial information: NCT01042379 .
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
Wei, Mei , Veer, Laura van ‘t , Alkhafaji, Silver , Hirst, Gillian L. , Chen, Nan , Borowsky, Alexander D. , Chien, Jo, Hirst, Gillian L , Elias, Anthony , Giridhar, Karthik V. , Goetz, Matthew P. , Mukhtar, Rita A. , Vaklavas, Christos , Veer, Laura J. van’t , Rugo, Hope S. , Symmans, W. Fraser , Swigart, Lamorna Brown , Onishi, Natsuko , Yee, Douglas , Hylton, Nola M. , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 612-612

10.1200/jco.2025.43.16_suppl.612 Get It

612 Background: EOP, an I-SPY2 sub-study, evaluates the tolerability and activity of novel endocrine strategies in stage 2/3 breast cancer (BC) patients (pts) predicted to have lower chemotherapy benefit. Laso, a selective estrogen receptor modulator (SERM), has shown favorable toxicity profile and activity in HR+/HER2- endocrine-resistant metastatic BC. Methods: Pts with Stage 2/3 HR+/HER2-, MammaPrint (MP) low risk BC were enrolled. Pts with MP High1 BC were included if clinically node-negative. Pts received oral laso 5 mg daily for six 28-day cycles. Laso was continued until the day prior to surgery. Premenopausal pts received ovarian function suppression (OFS) starting C2D1. The primary endpoint was feasibility (>75% of patients completing >75% study therapy). Baseline (T0), 3-wk (T1) biopsies, and the surgical specimen (T3) was assessed centrally for Ki-67. Breast MRI functional tumor volume (FTV) was performed at T0, T1, 12 weeks (T2), and pre-operatively (T3). Blood was collected for tumor informed ctDNA at T0, T1, T2, T3. Advance event (AE) was assessed using CTCAE V5. Results: From 3/2023 to 5/2024, 20 pts were enrolled. Median age 50.5 years, 50% premenopausal, and 1 male pt. 60% cN0, 80% MP low-risk signature. 18 (90%) pts completed >75% study therapy. Two pts discontinued treatment due to pt preference. Median Ki67 at T0 was 14.7%. At T1, 87.5% of pts remained or suppressed Ki67 to <10% and 37.5% suppressed to <2.7%. Ki67 at T1 was similar between pre-and postmenopausal pts despite OFS (Table). The median MRI FTV was 8.4 cc at T0, and 3.4 cc at T3. Median % FTV reduction from T0 to T3 was -47.5%. 2/20 pts (10%) achieved a modified PEPI score of 0. No patients achieved completed pathological response. Of the 16 pts with RCB results, 2 (12.5%) RCB-1, 6 (37.5%) RCB-2, 8 (50%) RCB-3 disease. 14 pts had ctDNA available at T0. 4/14 were ctDNA+ at T0, 2 of whom became ctDNA negative, and 2 remained ctDNA+. 10/14 pts were ctDNA negative at T0, 8 of whom remained negative, 2 became positive at T1 then cleared. All AEs were grade(G) 1 except 1 pt with G2 hot flashes. Most common AEs include hot flashes (85%), constipation (50%), fatigue (50%), and nausea (35%). One pt had G3 hypersensitivity and hypertension, both unrelated to therapy. Conclusions: Neoadjuvant laso demonstrates a favorable AE profile and promising anti-tumor activity in suppressing 3-wk Ki67 and MRI FTV change in pts with HR+ HER2-negative early BC. Ki67 suppression in premenopausal pts was seen in the absence of OFS. Clinical trial information: NCT01042379 . Ki67 expression at pre-treatment, and 3-wk time point. All Patients(n=20) Premenopausal (n=10) Postmenopausal (n=9) Median Ki67 expression Baseline 10.0% 12.5% 10.0% 3-wk 5.1% 3.0% 6.0% Number of pts with Ki67 expression <10% at 3-wk 87.5% 1 87.5% 85.7% Number of pts with Ki67 expression <2.7% at 3-wk 37.5% 50% 28.6% 1 Include the one male pt.
Validation of the International Consensus Classification (ICC) for systemic mastocytosis and the Mayo Alliance Prognostic Score (MAPS) in 910 consecutive patients.
Aperna, Fnu, Pardanani, Animesh , Kumar, Mahesh , Reichard, Kaaren K. , Yi, Cecilia Ysabel Arana, Butterfield, Joseph H. , Pongdee, Thanai , Gangat, Naseema , Tefferi, Ayalew, Chen, Dong , Orazi, Attilio , Tefferi, Ayalew

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e18596 Get It

e18596 Background: The International Consensus (ICC), but not the 5 th edition of the WHO classification (WHO5), distinguishes mature from immature mast cell leukemia (MCL) and systemic mastocytosis (SM) associated with myeloid neoplasm (SM-AMN) from SM associated with myeloid or lymphoid neoplasm (SM-AHN). The objectives of the current study were i) to assess prognostic input from disease classification by ICC vs. WHO5, and ii) to compare the predictive performance of the Mayo Alliance Prognostic scoring (MAPS) with other prognostic models and its prognostic interaction with the ICC-based morphologic classification. Methods: Study patients met diagnostic criteria per ICC/WHO5. MAPS risk variables included i) age >60 years, ii) hemoglobin below sex-adjusted lower limit of normal, iii) platelets <150 × 10⁹/L, iv) alkaline phosphatase above upper limit of normal, and v) advanced, including MCL, SM-AMN, and aggressive (ASM) vs. indolent/smoldering (ISM/SSM) SM. ICC-defined MCL includes only MCL-immature whereas WHO-defined MCL includes both MCL-immature and MCL-mature. WHO-defined SM-AHN includes SM-AMN and SM associated with lymphoid neoplasm (SM-ALN). Results: 910 Mayo Clinic patients with SM were diagnosed between 1968 and 2024 (median age 56 years). ICC categories were ISM/SSM (N=552), ASM (N=115), SM-AMN (N=235), and MCL (N=8). At median follow-up of 4 years, 345 (38%) deaths and 35 (3.8%) leukemic transformations were documented. Overall survival (OS) predictive performance at 5 years was superior with ICC (AUC 0.85), compared to WHO5 (AUC 0.83); median survival was 24.3 years in ISM/SSM, 5.8 years for ASM, 2.0 years for SM-AMN, 2.3 years for SM-AHN, 1.8 years for MCL-mature and 0.08 years for MCL-immature; the difference in OS was significant between MCL-immature and SM-AMN (p<0.01) but not between MCL-mature and SM-AHN (p=0.3). Similarly, OS was similar between MCL-mature and ASM (p=0.8) and between SM-ALN and ASM (p=0.08) but different between MCL-immature and ASM (p<0.01), SM-AMN and ASM (p<0.01), and MCL-mature and MCL-immature (p<0.01). Predictive performance at 5 years was superior with MAPS (AUC 0.91) and MAPS-molecular (AUC 0.91), compared to the mutation-adjusted risk score (MARS; AUC 0.82). Median OS estimates were not reached, 24.2, 11.7, 5.7, 2.6, and 0.7 years, in the presence of 0, 1, 2, 3, 4, or 5 of the forementioned MAPS risk factors. Among informative cases, ASXL1 mutation was the only genetic risk factor with MAPS-independent prognostic relevance. Prognostic inter-independence between ICC and MAPS was confirmed by multivariable analysis. Conclusions: The current study confirms the superior performance of MAPS, in regard to survival prediction, with little additional contribution from mutations. SM sub-classification by the ICC is prognostically independent of MAPS and more valuable than classification by WHO5.
Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.
Chen, Li , Lheureux, Stéphanie , O’Connor, C.J., Zamboni, Beth A., Patel, Kashish, Moscow, Jeff, Lucas, Andrew T. , Dumond, Julie B. , Mansfield, Aaron S. , Spreafico, Anna , O’Connor, Claire, Zamboni, William C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e15024 Get It

e15024 Background: Anetumab ravtansine (AR) is an antibody-drug conjugate (ADC) containing the microtubule inhibitor DM4. ADC drugs have high interpatient variability in pharmacokinetics and pharmacodynamics (PK/PD), which raises concerns whether current dosing based on body weight (mg/kg) is optimal. Thus, we evaluated the effects of patient characteristics, including novel biomarkers of the innate immune system (IIS), on the PK/PD of AR. Methods: Studies were performed in patients in three clinical trials of different cancers with AR as part of treatment: 1) platinum-resistant or refractory high-grade ovarian cancer treated with AR at 2.2mg/kg IV weekly plus bevacizumab(N = 19); 2) pleural mesothelioma treated with AR at 6.5 mg/kg IV every 3 weeks plus pembrolizumab(N = 28); and 3) mesothelin-positive advanced pancreatic adenocarcinoma treated with AR at 5.5-6.5 mg/kg IV every 3 weeks plus nivolumab (and ipilimumab or gemcitabine, N = 27). Intensive plasma PK sampling was performed after the first dose to calculate clearance (CL), volume of distribution (Vd), and area-under-the-plasma-concentration-time curve (AUC 0-inf ). The relationship between biomarkers of FcɣRs (CD64, CD32, CD16) on IIS blood cells, total body weight (TBW), body surface area (BSA), lean body mass (LBM), and sex with PK parameters and clinical outcomes were evaluated by pearson correlation, t-test and multivariate regression analysis. Population PK (popPK) methods further evaluated patient covariates and variability in PK. Results: Patients with higher IIS FcγR CD64 and/or higher TBW or higher BSA had higher AR ADC CL (p < 0.05). AR ADC CL was lower in females (0.030 ± 0.007 L/h) versus males (0.042 ± 0.006 L/h) (p < 0.05). Patients with stable disease and partial response had higher AR ADC AUC 0-inf versus patients with progressive disease AR ADC disposition was described by linear CL with two pathways for the release of the payload DM4, hydrolysis and the IIS. A time-varying drug-to-antibody ratio predicted the release of the DM4 payload. In the PopPK model, LBM and albumin were associated with CL of the AR ADC, LBM and IIS FcγR CD64 were associated with the Vd of the AR ADC, and LBM and age were associated with the CL of the released DM4. Conclusions: These results suggest that TBW-based dosing of AR ADC is not optimal, whereas precision dosing of antibodies and ADCs based on the use of novel metrics of body habitus, IIS biomarkers, and sex may be more appropriate to reduce PK variability and improve response.